The top pre-market NASDAQ stock market gainers are: ZST Digital Networks, Flow International, Spreadtrum Communications, Allos Therapeutics, and G-III Apparel Group. The top pre-market NASDAQ stock market losers are: Cerus, Energy Recovery, Marvell Technology Group, EV Energy Partners, and WPP.

Gainers

ZST Digital Networks, Inc. (ZSTN) stock jumped 20.50 percent to $7.23 in the pre-market trading. Profit for the fourth quarter was $8.51 million or 73 cents a share, up from $8.78 million or 28 cents a share last year. Revenue rose to $45.96 million from $30.35 million. The company expects full year 2011 revenue of $160 million to $175 million and earnings of $28 million to $30 million.

Flow International Corp. (FLOW) stock gained 12.20 percent to $4.60 in the pre-market trading. Profit for the third quarter was $1.2 million or 3 cents a share, compared to a loss of $0.7 million or 2 cents a share last year. Revenue rose 27 percent to $57.5 million. Analysts had expected profit of 2 cents a share on revenue of $54.18 million.

Spreadtrum Communications Inc. (SPRD) stock advanced 11.75 percent to $24.16 in the pre-market trading, as its fourth quarter earnings exceeded Street view. Profit was $29.96 million or $0.56 per American Depositary Share (ADS), higher than $1.45 million or $0.03 per ADS last year. Adjusted profit was $32.72 million or $0.61 per ADS, higher than $2.91 million or $0.06 per ADS last year. Revenue surged 199.5 percent to $126.5 million. Analysts had expected profit of $0.52 per ADS on revenue of $122.23 million.

Spreadtrum expects first quarter revenue of $130 million to $135 million, while Street predicts $109.29 million. The company anticipates gross margin of 41.5 percent to 42.5 percent.

Allos Therapeutics, Inc. (ALTH) stock climbed 11.29 percent to $3.45 in the pre-market trading. Fourth quarter loss narrowed to $18.1 million or 17 cents a share from $22.9 million or 22 cents a share last year. Sales rose to $11.7 million from $3.6 million. Analysts had expected a loss fo 18 cents a share on revenue of $11.2 million. The company expects fiscal 2011 total operating costs and expenses, excluding cost of sales and non-cash stock-based compensation expense, of about $95 million to $98 million.

Separately, Allos Therapeutics said it has reached an agreement with the U.S. FDA under its Special Protocol Assessment process for the design of the company's Phase 3 clinical trial of Folotyn in patients with previously undiagnosed peripheral T-cell lymphoma (PTCL). The study will seek to enroll newly diagnosed patients with PTCL who have achieved a response following initial treatment with a CHOP-based therapy.

The Phase 3 clinical trial will seek to establish the safety and efficacy of sequential Folotyn versus observation in patients with previously undiagnosed PTCL who have achieved a response following initial treatment with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or CHOP-based chemotherapy. The co-primary endpoints will be progression-free survival and overall survival. The company expects to initiate this Phase 3 clinical trial of Folotyn in 2011.

G-III Apparel Group, Ltd. (GIII) stock grew 10.06 percent to $43 in the pre-market trading.

Losers

Cerus Corp. (CERS) stock plunged 10.12 percent to $3.02 in the pre-market trading. Loss for the fourth quarter narrowed to $2.6 million or 6 cents a share from $4.9 million or 13 cents a share last year. Revenue rose to $6.5 million from $5.5 million.

Energy Recovery, Inc. (ERII) stock tumbled 8.43 percent to $3.15 in the pre-market trading, as it guided fiscal 2011 below Street view. The company expects fiscal 2011 loss of 13 cents to 19 cents a share and revenue of $36 million to $45 million, while Street predicts breakeven a share on revenue of $56.01 million.

Energy Recovery posted fourth quarter earnings of $496,000 or 1 cent a share, down from $1.65 million or 3 cents a share last year. Revenue fell to $13.01 million from $15.73 million. Analysts had expected breakeven a share on revenue of $18.06 million.

Marvell Technology Group Ltd. (MRVL) stock fell 6.15 percent to $17.10 in the pre-market trading, as its fourth quarter earnings and revenue missed Street view. Adjusted profit was $273 million or 40 cents a share, compared to $266 million or 40 cents a share last year. Revenue rose 7 percent to $901 million. Analysts had expected profit of 42 cents a share on revenue of $925.64 million. The company said its board of directors authorized it to buyback up to an additional $500 million, for a total of $1 billion, of its outstanding common shares.

In a conference call, Marvell said it expects first quarter revenue of $800 million to $850 million, the midpoint representing an worse-than-expected 8 percent dip from the fourth quarter. The company expects stores to decline low- to mid-single digit sequentially, networking to be essentially flat and mobile and wireless to decline over 20 percent. The company expects adjusted earnings of 30 cents a share, plus or minus a couple of pennies. Street predicts profit of 37 cents a share on revenue of $889.94 million.

EV Energy Partners LP (EVEP) stock slid 4.64 percent to $44.15 in the pre-market trading. The company said it began an underwritten public offering of 3.0 million of its common units representing limited partner interests. The company plans to grant the underwriters a 30-day option to purchase up to 450,000 additional common units to cover over-allotments, if any.

EV Energy plans to use the net proceeds from the offering, including the proceeds from any exercise of the over-allotment option of common units, to repay indebtedness under its existing revolving credit facility.

WPP plc (WPPGY) stock decreased 3.56 percent to $65.74 in the pre-market trading. The company announced preliminary results for 2010 reporting a pre-tax profit of 851.3 million pounds compared to 662.6 million pounds a year ago. Headline profit before taxation was up to 1.03 billion pounds compared to 812.2 million pounds last year.

Headline earnings were 759.1 million pounds or 56.7 pence per share compared to 550.0 million pounds or 44.4 pence per share in the year ago period. Revenue for the period was up to 9.33 billion pounds compared to 8.68 billion pounds in the prior year. Like-for-like revenue up 5.3 percent.

NASDAQ Stock Market Lymphoma